| Criteria: |
|
DISEASE CHARACTERISTICS:
- Histologically confirmed recurrent or persistent ovarian epithelial, fallopian tube,
or primary peritoneal carcinoma
- Histologic confirmation of the original primary tumor via pathology report
required
- Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1
dimension (longest diameter to be recorded) as ≥ 10 mm by CT scan, MRI, or caliper
measurement by clinical exam OR ≥ 20 mm by chest x-ray
- Lymph nodes must be ≥ 15 mm in short axis when measured by CT scan or MRI
- Has ≥ 1 "target lesion" to be used to assess response, as defined by RECIST criteria
- Tumors within a previously irradiated field will be designated as "non-target"
lesions unless progression is documented or a biopsy is obtained to confirm
persistence ≥ 90 days following completion of radiotherapy
- Must have received 1 prior platinum-based chemotherapeutic regimen containing
carboplatin, cisplatin, or another organoplatinum compound for management of primary
disease
- Initial treatment may have included intraperitoneal therapy, high-dose therapy,
consolidation therapy, non-cytotoxic agents, or extended therapy administered
after surgical or non-surgical assessment
- Must have a platinum-free interval of < 12 months, progressed during
platinum-based therapy, or have persistent disease after platinum-based therapy
- One additional cytotoxic regimen for management of recurrent or persistent
disease allowed
- Ineligible for a higher priority GOG protocol, if one exists (e.g., any active GOG
phase III protocol for the same patient population)
PATIENT CHARACTERISTICS:
- GOG performance status (PS) 0-2 (for patients who received 1 prior regimen)
- GOG PS 0-1 (for patients who received 2 prior regimens)
- ANC ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
- Hemoglobin ≥ 9 g/dL
- Creatinine ≤ 1.5 times upper limit of normal (ULN)
- Bilirubin ≤ 1.5 times ULN
- SGOT ≤ 3.0 times ULN
- Alkaline phosphatase ≤ 2.5 times ULN
- PTT ≤ 1.5 times ULN
- INR ≤ 1.5 times ULN
- Proteinuria ≤ 1+ by urinalysis OR ≤ 1 g/24 hrs by 24-hour urine collection
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No neuropathy (sensory or motor) > grade 1
- No peripheral edema or lymphedema > grade 2
- No active bleeding diathesis
- No thromboembolic or ischemic event within the past 12 months, including any of the
following:
- Deep venous thrombosis
- Pulmonary embolism
- Transient ischemic attack
- Cerebral infarction
- Myocardial infarction
- No serious or non-healing wound
- No known HIV or hepatitis C positivity or chronic or active hepatitis B
- No active infection requiring antibiotics
- Uncomplicated urinary tract infection allowed
- No other concurrent serious infection or nonmalignant medical illness that is
uncontrolled or whose control may be jeopardized by study treatment
- No psychiatric condition or other condition that would preclude giving informed
consent or meeting study requirements
- No history of primary endometrial cancer unless all of the following criteria are
met:
- No greater than stage IB disease
- No more than superficial myometrial invasion
- No vascular or lymphatic invasion
- No poorly differentiated subtypes, including papillary serious, clear cell, or
other FIGO grade 3 lesions
- No other invasive malignancies within the past 3 years except for nonmelanoma skin
cancer or localized cancer of the breast, head and neck, or skin
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- Recovered from prior surgery, radiotherapy, or chemotherapy
- No prior cancer treatment that would contraindicate study treatment
- No prior fully human anti-HGF monoclonal antibody AMG 102 or other HGF/c-met pathway
inhibitors
- No prior non-cytotoxic therapy for management of recurrent or persistent disease
- Prior biologic (non-cytotoxic) therapy as part of primary treatment regimen
allowed
- No prior radiotherapy to any portion of the abdominal cavity or pelvis OTHER THAN for
the treatment of ovarian, fallopian tube, or primary peritoneal cancer within the
past 3 years
- Prior radiotherapy for localized cancer of the breast, head and neck, or skin is
allowed provided it was completed > 3 years ago and the patient remains free of
recurrent or metastatic disease
- No prior chemotherapy for any abdominal or pelvic tumor OTHER THAN for the treatment
of ovarian, fallopian tube, or primary peritoneal cancer within the past 3 years
- Prior adjuvant chemotherapy for localized breast cancer allowed provided it was
completed > 3 years ago and the patient remains free of recurrent or metastatic
disease
- More than 30 days since prior surgery (14 days for minor surgical procedures)
- Central venous catheter placement allowed at any time point before study
enrollment provided the patient has recovered and any surgical wound has healed
- At least 1 week since prior hormonal therapy directed at the malignant tumor
- At least 3 weeks since any other prior therapy directed at the malignant tumor,
including immunologic agents
- More than 7 days since prior and no concurrent therapeutic anti-coagulation therapy
with warfarin, heparin, or low molecular weight heparin
- Low-dose warfarin (≤ 2 mg orally daily) for prophylaxis against central venous
catheter thrombosis allowed
|